Early chemohormonal therapy in prostate cancer: preliminary data and randomized trials.
Chemotherapy was traditionally perceived to be ineffective for prostate cancer and was only administered to patients with symptomatic hormone-refractory disease. Although previous reviews have confirmed this belief, recent studies have demonstrated significant antitumor activity with chemotherapy regimens. This article highlights the preliminary results of recent studies involving chemohormonal therapy.
Petrylak
Daniel P
DP
Department of Medicine, College of Physicians and Surgeons, Columbia-Presbyterian Medical Center, 161 Fort Washington Avenue, New York, NY 10032, USA. dpp5@columbia.edu
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D004358:Drug Therapy; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013997:Time Factors
D018931:Antineoplastic Agents, Hormonal; D017430:Prostate-Specific Antigen